|
|
|
17.10.24 - 07:55
|
XFRA : DU8: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
GENETIC TEC. DU8 AU000000GTG7 BAW/UFN...
|
|
|
|
|
|
|
23.09.24 - 14:33
|
Join Genetic Technology′s Exclusive Live Investor Webinar and Q&A Session on October 2 (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET....
|
|
|
|
|
|
|
|
|
15.08.24 - 14:03
|
Genetic Technologies Announces Global Launch of geneType™ on Wholly Owned EasyDNA platform (GlobeNewswire EN)
|
|
|
CHARLOTTE, N.C., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce the global launch of the geneType™ Risk Assessment portfolio on our wholly owned EasyDNA platform currently selling in 42 countries, setting the stage for the potential significant expansion of the Company's current A$7.5m annual revenues....
|
|
|
|
|
09.08.24 - 14:03
|
Join Genetic Technology′s Exclusive Live Investor Webinar and Q&A Session on August 15 (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on August 15, 2024, at 4:15 p.m. ET....
|
|
|
|
|
04.08.24 - 21:43
|
XFRA : CAPITAL ADJUSTMENT INFORMATION - 06.08.2024 - AU000000GTG7 (XETRA)
|
|
|
Das Instrument DU8 AU000000GTG7 GENETIC TEC. EQUITY wird cum Kapitalmassnahme gehandelt am 05.08.2024 und ex Kapitalmassnahme am 06.08.2024
The instrument DU8 AU000000GTG7 GENETIC TEC. EQUITY is traded cum capital adjustment on 05.08.2024 and ex capital adjustment on 06.08.2024...
|
|
|
26.07.24 - 14:06
|
Genetic Technologies Strategic Restructure Driving USA Sales Growth (GlobeNewswire EN)
|
|
|
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focus on sales growth (particularly in the Company's largest market in the United States) and move the Company's operations to an outsourced / collaborations approach (rather than the more expensive current in house laboratory operations)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
